Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca
  1. Pubblicazioni

Pelvic bone marrow dose-volume predictors of late lymphopenia following pelvic lymph node radiation therapy for prostate cancer

Articolo
Data di Pubblicazione:
2024
Citazione:
Pelvic bone marrow dose-volume predictors of late lymphopenia following pelvic lymph node radiation therapy for prostate cancer / Pavarini, Maddalena; Alborghetti, Lisa; Aimonetto, Stefania; Maggio, Angelo; Landoni, Valeria; Ferrari, Paolo; Bianculli, Antonella; Petrucci, Edoardo; Cicchetti, Alessandro; Farina, Bruno; Ubeira-Gabellini, Maria Giulia; Salmoiraghi, Paolo; Moretti, Eugenia; Avuzzi, Barbara; Giandini, Tommaso; Munoz, Fernando; Magli, Alessandro; Sanguineti, Giuseppe; Magdalena Waskiewicz, Justyna; Rago, Luciana; Cante, Domenico; Girelli, Giuseppe; Vavassori, Vittorio; Di Muzio, Nadia Gisella; Rancati, Tiziana; Cozzarini, Cesare; Fiorino, Claudio. - In: RADIOTHERAPY AND ONCOLOGY. - ISSN 0167-8140. - 195:(2024). [10.1016/j.radonc.2024.110230]
Abstract:
Background and purpose: Given the substantial lack of knowledge, we aimed to assess clinical/dosimetry predictors of late hematological toxicity on patients undergoing pelvic-nodes irradiation (PNI) for prostate cancer (PCa) within a prospective multi-institute study. Materials and methods: Clinical/dosimetry/blood test data were prospectively collected including lymphocytes count (ALC) at baseline, mid/end-PNI, 3/6 months and every 6 months up to 5-year after PNI. DVHs of the Body, ileum (BMILEUM), lumbosacral spine (BMLS), lower pelvis (BMPELVIS), and whole pelvis (BMTOT) were extracted. Current analysis focused on 2-year CTCAEv4.03 Grade >= 2 (G2+) lymphopenia (ALC < 800/mu L). DVH parameters that better discriminate patients with/without toxicity were first identified. After data pre-processing to limit overfitting, a multi-variable logistic regression model combining DVH and clinical information was identified and internally validated by bootstrap. Results: Complete data of 499 patients were available: 46 patients (9.2 %) experienced late G2+ lymphopenia. DVH parameters of BMLS/BMPELVIS/BMTOT and Body were associated to increased G2+ lymphopenia. The variables retained in the resulting model were ALC at baseline [HR = 0.997, 95 %CI 0.996-0.998, p < 0.0001], smoke (yes/no) [HR = 2.9, 95 %CI 1.25-6.76, p = 0.013] and BMLS-V >= 24 Gy (cc) [HR = 1.006, 95 %CI 1.002-1.011, p = 0.003]. When acute G3+ lymphopenia (yes/no) was considered, it was retained in the model [HR = 4.517, 95 %CI 1.954-10.441, p = 0.0004]. Performances of the models were relatively high (AUC = 0.87/ 0.88) and confirmed by validation. Conclusions: Two-year lymphopenia after PNI for PCa is largely modulated by baseline ALC, with an independent role of acute G3+ lymphopenia. BMLS-V24 was the best dosimetry predictor: constraints for BMTOT (V10Gy < 1520 cc, V20Gy < 1250 cc, V30Gy < 850 cc), and BMLS (V24y < 307 cc) were suggested to potentially reduce the risk.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Radiotherapy; Hematological toxicity; Lymphopenia; Prostate cancer; NTCP; Predictive models
Elenco autori:
Pavarini, Maddalena; Alborghetti, Lisa; Aimonetto, Stefania; Maggio, Angelo; Landoni, Valeria; Ferrari, Paolo; Bianculli, Antonella; Petrucci, Edoardo; Cicchetti, Alessandro; Farina, Bruno; Ubeira-Gabellini, Maria Giulia; Salmoiraghi, Paolo; Moretti, Eugenia; Avuzzi, Barbara; Giandini, Tommaso; Munoz, Fernando; Magli, Alessandro; Sanguineti, Giuseppe; Magdalena Waskiewicz, Justyna; Rago, Luciana; Cante, Domenico; Girelli, Giuseppe; Vavassori, Vittorio; Di Muzio, Nadia Gisella; Rancati, Tiziana; Cozzarini, Cesare; Fiorino, Claudio
Autori di Ateneo:
DI MUZIO NADIA GISELLA
Link alla scheda completa:
https://iris.unisr.it/handle/20.500.11768/170837
Pubblicato in:
RADIOTHERAPY AND ONCOLOGY
Journal
RADIOTHERAPY AND ONCOLOGY
Series
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.5.1.0